Guggenheim Strategic Opportunities Fund (GOF) Faces Investor Scrutiny Amid Report On Distributions Funding, Portfolio Quality - HBSS

Luffa AI said it received a strategic equity investment from Hong Kong-listed GoFintech Quantum Innovation (00290.HK), valuing Luffa at US$220 million. The firms plan collaboration on AI, quantum security, blockchain and fintech compliance. Luffa reported 3 million downloads, 2 million users and 150,000 daily active users as of Feb 2026.

Broadcom (AVGO) stock fell 0.3% premarket after a Financial Times report stated Chinese authorities are auditing its networking hardware in state-backed data centers, aiming to reduce reliance on foreign tech. The survey found Broadcom switches may account for 90% of hardware used by state-owned firms, potentially leading to reduced usage. Huawei and other Chinese suppliers could benefit. Retail sentiment on AVGO remains bearish.

General Motors (GM) received $500M in tariff relief. Lawmakers seek consumer refunds and revenue disclosure. GM CEO Mary Barra attended a White House dinner with Chinese President Xi, discussing U.S.-China auto policies.

A U.S. judge dismissed Michigan's antitrust suit against BP PLC, ruling the plaintiffs failed to prove alleged conspiracy caused claimed energy overcharges. Separately, BP sold its stake in the Sapref refinery to Central Energy Fund for 1 rand, exiting the asset.

NewAmsterdam Pharma (NAMS) received European Commission approval for its cholesterol drug obicetrapib, marking its first global regulatory approval. The stock has seen a recent bounce, up 3.28% to $23.32, following a period of decline. Analysts suggest the company may be undervalued with an implied fair value of $50.92, but risks include potential trial failures and equity dilution.

AstraZeneca received EU approval for Trixeo Aerosphere, a triple-combination asthma inhaler for patients aged 12+ with uncontrolled asthma. The therapy, backed by Phase III trial data, is already marketed as Breztri in other regions. This approval strengthens AstraZeneca's respiratory portfolio and growth strategy.